Previous 10 | Next 10 |
Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright. Opioid settlement another reason the stock added 30% after the earnings report. When Teva Pharmaceutical Industries Limited ( TEVA ) posted second-quarter results, the ...
Women’s healthcare company Organon ( NYSE: OGN ) and life science company Cirqle Biomedical announced a research collaboration and license agreement on Thursday to develop and commercialize an experimental contraceptive candidate. According to pre-clinical data, the...
Collaboration continues to expand portfolio in women’s health to help address unmet needs Organon (NYSE: OGN), a global women’s healthcare company, and Cirqle Biomedical today announced they have entered into a research collaboration and exclusive license agree...
The shares of Swiss biotech ObsEva SA ( NASDAQ: OBSV ) plunged ~78% after the company announced Wednesday it intends to begin a corporate restructuring after the FDA cited issues related to the marketing application of uterine fibroids therapy linzagolix. After the FDA r...
Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2022 financial results on August 4, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on...
Cognizant Teams Up with Organon to Speed Delivery of Pharmaceutical Products and Improve Women's Healthcare PR Newswire Organon's Manufacturing Site Efficiencies Expected to Improve Supply Chain Management and Speed Healthcare Product Delivery TEANACK, N.J. ,...
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
Organon was formed when pharma giant Merck spun out its Established Brands, Women's Health and Biosimilars divisions into a new entity. The deal enabled Merck to realise a $9bn tax windfall, and Organon initially looked fundamentally undervalued at a P/S ratio of <1.5x. Organon...
Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...
Baxter’s 8.7% 5-yr return on invested capital, ROIC, is quite a bit below its peers. TTM ROIC of 6.1% is about half the Industry ETF avg of 11.1%. Long-term debt ballooned from $5.8 billion at the end of 2020 to $17.1 billion as of March 2022. Goodwill assets also jumped t...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...